Muscle Loss and Nerve Damage in Adults With Type 1 Diabetes
Studies whether muscle loss is linked to nerve damage in adults with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Association Between Sarcopenia And Diabetic Neuropathy In Adults With Type 1 Diabetes, A Pilot Study
Key facts
- Where
- Rome, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 80 years old?
Source: NCT06902597, who can take part
Where in Italy
- Fondazione Policlinico Universitario A. Gemelli IRCCS; UOC DiabetologiaRome, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Trial code
- NCT06902597
- Record updated
- 30 March 2025
- Original description
Monocentric interventional prospective study to evaluate the prevalence of sarcopenia in adults with type 1 diabetes (T1DM) and to evaluate the association between diabetic neuropathy and sarcopenia in subjects with T1DM; to evaluate the prevalence of dynapenia in adults with T1DM and its association with diabetic neuropathy.Read full original descriptionShow less
Association Between Sarcopenia And Diabetic Neuropathy In Adults With Type 1 Diabetes, A Pilot Study
Monocentric interventional prospective study to evaluate the prevalence of sarcopenia in adults with type 1 diabetes (T1DM) and to evaluate the association between diabetic neuropathy and sarcopenia in subjects with T1DM; to evaluate the prevalence of dynapenia in adults with T1DM and its association with diabetic neuropathy.
Inclusion: Age 50-80 years, both sexes; Diagnosis of T1DM for at least 10 years, in both multiple daily injections of insulin (MDI) and continuous subcutaneous insulin infusion (CSII); Informed consent before any study activity; Ability to fully perform all protocol activities.
Exclusion: Previous diagnosis of T2DM; Previous diagnosis of dementia; Previous history of stroke or cerebrovascular disease; Untreated hypothyroidism or hyperthyroidism or not well controlled hypothyroidism or hyperthyroidism with current therapy (TSH >5 or TSH <0.15); Corticosteroid and/or estrogen-progestogen therapy for at least 12 months in medical history; On going treatment with antiretroviral therapy; On going treatment with immunosuppressive therapy, e.g. cyclosporine, tacrolimus; On going treatment with anti-epileptic drugs; Presence of heart failure (NYHA class III and IV); Presence of muscular disease; Diagnosis of neurodegenerative disease (e.g. multiple sclerosis, Parkinson's disease); Diagnosis of coeliac disease; Diagnosis of chronic inflammatory bowel disease; Active cancer or therapy; eGFR evaluated through CKD-EPI formula <20 ml/min /1.73m2 , estimated on previous creatinine dosage; Alcohol abuse or consumption of more than 14 alcoholic units weekly; Pregnancy; Primary hyperparathyroidism.